Milestones in NSCLC

Welcome to the Resource Center “Milestones in Non-Small-Cell Lung Cancer (NSCLC)” launched by Elsevier and the Journal of Thoracic Oncology at the World Conference on Lung Cancer 2016 in Vienna.

Recent years have seen much progression in learning about the biology of lung cancer cells and the mechanisms that control their growth and spread. This has led to define biomarkers and oncogenic drivers, to develop new screening systems such as liquid biopsy and improving patients outcome with targeted strategies and immunotherapies.

The Resource Center “Milestones in NSCLC” is dedicated to providing you with groundbreaking discoveries in diagnosis and management of NSCLC. Our aim is to supply health care professionals with clinically relevant information to enhance knowledge about lung cancer and help meet the challenges faced in today’s medical practice.

Article of the month

  • Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

    Topic: Therapy

    Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O'Brien M, Rao S, Hotta K, Leiby MA, Lubiniecki GM, Shentu Y, Rangwala R, Brahmer JR; KEYNOTE-024 Investigators

    New England Journal of Medicine, Volume 375, Issue 19, 10 November 2016, Pages 1823-1833

    Commentary by Nir Peled

    The success of this milestone study is an additional proof for the strength of precision medicine....

New videos

  • WCLC16 Prof. Dr. med. Martin Reck

    In this video, Dr. Martin Reck discusses the emergence of the immunotherapy and the positive results of four randomized trials on immunotherapy vs. chemotherapy, showing benefit in overall survival. Dr. Reck also mentions that in selected patients immunotherapy might be better than chemotherapy and the treatment plan for a specific population of patients with autoimmune diseases at the baseline.
  • WCLC16 Dr. Federico Cappuzzo, MD, PhD

    Therapy of EG for mutated lung cancer was discussed during the world conference on lung cancer held in Vienna. A lot of new data and already available data on EG for mutated lung cancer was discussed in detail during the conference. Dr. Federico Cappuzzo, (Director Medical Oncology Department, at Ospedale Civile, Livorno) gave a lot insights about the management of EG for mutated NSCLC with the new molecule osimertinib, the new strategy of diagnosis based on clinical practice and the new management approach of NSCLC.
  • WCLC16 Dr. Enriqueta Felip, MD, PhD

    This session with Dr. Felip discusses the overall landscape of ALK inhibitors for treatment of NSCLC. She discusses the various available ALK inhibitors currently including crizotinib, ceritinib, alectinib and the possible treatment modalities with these drugs either as monotherapy or in combination. She also gives a brief overview of the various randomized trials which have had positive results with these inhibitors and stressed on the need for further trials and data in this area.

New this month

Stay informed

Subscribe to our E-Alert to keep up to date with the new items in the Resource Centre

Society partner

Made possible by an educational grant from

Please note that Lilly Oncology has no editorial control over the content of this Resource Centre. The Resource Centre and all content therein has been subjected to an independent editorial review.

ECCO 2017

Debating the optimal management in advanced and metastatic lung cancer: The right treatment for the right patient at the right time

Saturday 28 january

13:15 - 14:45

RAI, Room Weinberg

Amsterdam, Netherlands

This educational activity is provided by Elsevier. Independent sponsorship for this educational activity was provided by Lilly Oncology.


Interactive Case Reports

Read more about recent cases from the Journal of Thoracic Oncology. Test your knowledge and answer the questions following the case to get immediate feedback.

Solange Peters

Editor in Chief

Tom Stinchcombe

Advisory Editor

Nir Peled

Advisory Editor

Stefan Zimmermann

Managing Editor

About the Editors

All content available on the Milestones in NSCLC Resource Centre, including original and review articles, interviews, guidelines, congress highlights, case reports is independently selected by the members of the Editorial Board.